<DOC>
	<DOC>NCT00627120</DOC>
	<brief_summary>To assess the safety and tolerability of a single dose of VGX-1027 in the range of 1-800mg.</brief_summary>
	<brief_title>Phase I Safety and Pharmacokinetic Study of VGX-1027 in Healthy Subjects</brief_title>
	<detailed_description>This study will evaluate: - The safety and tolerability of a single dose of VGX-1027 as determined by: adverse event reporting, clinical laboratory results, vital signs, physical examinations, and electrocardiograms (ECGs). - The pharmacokinetic (PK) profile of VGX-1027 maximum concentration (Cmax)</detailed_description>
	<criteria>Must give written informed consent. Healthy subjects as determined by no clinically significant deviation from normal as judged by the investigator in medical history, physical examination, ECGs and clinical laboratory evaluations Body Mass Index of 1830kg/m^2 inclusive Males or females ages 1860, inclusive. Women who are not of childbearing potential may enroll. Women must have a negative pregnancy test within 72 hours prior to start of study drug administration or be surgically sterile. Women who are of childbearing potential Women who are pregnant or breastfeeding Women with a positive pregnancy test on enrollment or prior to study drug administration Male subjects who are unwilling to agree to practice barrier contraception during the study and for three months following dosing Any significant acute or chronic mental illness Current or recent gastrointestinal disease that may impact the absorption of the drug Any major surgery within 4 weeks of enrollment Donation of blood or plasma to a blood bank or in a clinical study (except screening visit) within 4 weeks of enrollment Blood transfusion within 4 weeks of enrollment Inability to tolerate oral medication Inability to be venipunctured and/or tolerate venous access Recent (within 6 months) drug or alcohol abuse History of bleeding disorder History of head trauma or seizures Any other sound medical, psychiatric and/or social reason as determined by the Investigator Evidence of organ dysfunction or any clinically significant deviation from normal in vital signs, physical examination, ECG, or clinical laboratory determinations Positive urine screen for drugs of abuse Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, HIV 1/2 antibody History of any significant drug allergy Exposure to any investigational drug within 4 weeks prior to enrollment or greater that 4 weeks for investigational drugs that may have a longer halflife Use of any prescription drugs or over the counter acid controllers within 4 weeks prior to enrollment Use of any other drugs, including over the counter vitamins, medications and/or herbal preparations within 2 weeks prior to enrollment Use of oral, injectable or implantable hormonal contraceptive agents within 3 months prior to enrollment Use of alcohol containing beverages within 1 week prior to enrollment Use of grapefruit containing products within 1 week prior to enrollment Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g. infectious disease) illness must not be enrolled into this study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>healthy volunteers</keyword>
</DOC>